Your browser doesn't support javascript.
loading
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Rugo, H S; O'Shaughnessy, J; Boyle, F; Toi, M; Broom, R; Blancas, I; Gumus, M; Yamashita, T; Im, Y-H; Rastogi, P; Zagouri, F; Song, C; Campone, M; San Antonio, B; Shahir, A; Hulstijn, M; Brown, J; Zimmermann, A; Wei, R; Johnston, S R D; Reinisch, M; Tolaney, S M.
Afiliación
  • Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco. Electronic address: Hope.Rugo@ucsf.edu.
  • O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.
  • Boyle F; Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Sydney; University of Sydney, Sydney, Australia.
  • Toi M; Kyoto University Hospital, Kyoto, Japan.
  • Broom R; Auckland City Hospital, Auckland, New Zealand.
  • Blancas I; Hospital Universitario Clínico San Cecilio, Granada; Medicine Department, University of Granada, Granada, Spain.
  • Gumus M; Istanbul Medeniyet University, School of Medicine, Istanbul, Turkey.
  • Yamashita T; Kanagawa Cancer Center, Yokohama, Japan.
  • Im YH; Division of Hematology/Medical Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Rastogi P; University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA.
  • Zagouri F; National and Kapodistrian University of Athens, Department of Clinical Therapeutics, School of Medicine, Athens, Greece.
  • Song C; Fujian Medical University Union Hospital, Fujian, China.
  • Campone M; Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes/Saint-Herblain, France.
  • San Antonio B; Eli Lilly and Company, Indianapolis, USA.
  • Shahir A; Eli Lilly and Company, Indianapolis, USA.
  • Hulstijn M; Eli Lilly and Company, Indianapolis, USA.
  • Brown J; Eli Lilly and Company, Indianapolis, USA.
  • Zimmermann A; Eli Lilly and Company, Indianapolis, USA.
  • Wei R; Eli Lilly and Company, Indianapolis, USA.
  • Johnston SRD; Royal Marsden NHS Foundation Trust, London, UK.
  • Reinisch M; Breast Unit, Kliniken Essen-Mitte, Essen, Germany.
  • Tolaney SM; Dana-Farber Cancer Institute, Boston, USA.
Ann Oncol ; 33(6): 616-627, 2022 06.
Article en En | MEDLINE | ID: mdl-35337972
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article